• BRIDGING GAPS IN ORAL
    HEALTH WITH
    INNOVATIVE SOLUTIONS

    PURPOSE

    Working to bridge the missing link in patient-centered oral care.

    True Node Sciences Inc. (TNS), based in New York, is a biotech company focused on addressing unmet medical needs in oral health, with a primary emphasis on periodontal diseases.

    Periodontitis, recognized as a pandemic by specialists, affects approximately 11% of the global population, underscoring the urgent need for innovative solutions.

    TNS is actively working to develop cost-effective therapies for periodontitis while addressing a range of oral health challenges. By striving to provide the missing pharmaceutical link for more effective treatments, TNS aims to create solutions that treat periodontitis at its root.

    Guided by a commitment to accessibility and innovation, TNS is working to advance oral healthcare by developing therapies that can address critical patient needs.

    Innovating the way oral diseases are treated

    PGR-1

    COUNTER-REGULATES ACUTE INFLAMMATION, STIMULATING MOLECULAR AND CELLULAR EVENTS TO PROMOTE RESOLUTION.

    CONTROL OF THE LOCAL EXAGGERATED IMMUNE RESPONSE/ANTIBACTERIAL EFFECT.

    Research shows a reciprocal relationship between the microbiome and inflammatory/immune responses in the mucous membrane. In mucosal inflammation, both healthy and disease-associated microbial species increase, perpetuating chronic systemic inflammation and leading to an irreversible state. Factors such as aging, smoking, and obesity further contribute to the development of various mucosal inflammatory diseases.

    Existing pharmaceutical treatments, including antibacterials combined with NSAIDs and corticosteroids, have historically been inadequate in resolving chronic inflammation and dysregulated immune responses, often resulting in recurrent oral inflammatory diseases.

    PGR-1 is a proprietary, innovative formulation combining a statin and an antibacterial agent designed to address the etiopathogenesis of mucosal inflammatory diseases. PGR-1 targets both microbial and immune dysfunction by reducing microbial biomass through bactericidal effects and rebalancing dysfunctional immune responses that drive chronic oral mucosal inflammation. By reducing microbial biomass to optimal levels and promoting a functional immune response, PGR-1 aims to transition the microbiota from a dysbiotic to a symbiotic state, fostering long-term mucosal health.

    TEAM

    MEET OUR TEAM, A GROUP OF EXPERIENCED PROFESSIONALS COMMITTED TO DEVELOPING INNOVATIVE SOLUTIONS FOR UNMET NEEDS.

    FOUNDERS

    FELIPE GALVAN / CO-FOUNDER AND CEO

    Felipe is a versatile professional with a BS in Chemical Engineering from Universidad de Santiago de Chile, complemented by qualifications in Business Management and Clinical Applied Biochemistry. His experience includes research at Germany's University of Karlsruhe-TH.

    With over 15 years in multidisciplinary leadership across research, healthcare, and industry, Felipe excels in strategic planning and stakeholder management. His entrepreneurial skills have driven successful business ventures, leveraging his unique blend of technical expertise and commercial acumen. Felipe's ability to bridge scientific innovation with market opportunities has established him as a dynamic leader in both corporate and startup environments.

    LINKEDIN PROFILE
    DR. DAVID ROSENBERG / CO-FOUNDER AND CMO

    David is Dental Surgeon from the Universidad de Chile, he pursued a MSc in Periodontology and Osseointegration at the Catholic University of Leuven (KUL Leuven, Belgium) and PhD at the International University of Catalunya, researching topics in the areas of Periodontology and Oral Medicine.

    Between 2009 and 2019, David serves as the Director of Graduate Studies of the Faculty of Dentistry and part of the academic staff of Department of Oral and Maxillofacial Surgery at the Los Andes University, Chile. Dr. Rosenberg is an established lecturer and well-published researcher in International journals. He is an active member of the European Association of Osseointegration and the Academy of Osseointegration.

    LINKEDIN PROFILE
    DR. RAJESH V. LALLA / PRINCIPAL INVESTIGATOR

    Dr. Lalla, a board-certified clinician and scholar, is a renowned authority in evidence-based dentistry and clinical research. As a professor and Associate Dean for Research at UConn's School of Dental Medicine, he leads a thriving NIH-funded research program. With over 125 publications, he has also developed educational courses and held leadership roles in international organizations. His groundbreaking work on oral side effects of cancer therapy has profoundly improved patient care. In 2020, he was honored with the Evidence-based Dentistry Accomplished Faculty Award for his exceptional contributions to research, practice, and education.

    LINKEDIN PROFILE

    BOARD OF ADVISORS

    DR. TOMAS GALVAN / CO-FOUNDER AND DIRECTOR

    Dental Surgeon from the Universidad de Chile and former professor of Chemistry at the Faculty of Dentistry at the University of Chile.

    40 years of experience, he has developed many initiatives in the public and private sectors. Scientist and serial entrepreneur.

    Responsible for the development pipeline at Ingalfarma SpA an oral pharmaceutical Company based in Santiago de Chile.

    Inventor and author of a large number of international patents.

    LINKEDIN PROFILE
    DR. PABLO VALENZUELA / DIRECTOR AND SCIENTIFIC ADVISOR

    Ph.D. in Chemistry at Northwestern University, Post Doctor at University of California San Francisco and held a position as Professor in the Biochemistry Department of that institution.

    In 1981 he founded Chiron Corporation, which a decade later was the second-largest biotechnology company in the world.

    Valenzuela was responsible for the development of biotech products with a market value of nearly 8 billion dollars.

    Inventor in more than 50 patents in Chile and abroad, in 1997 he cofounded Fundación Ciencia & Vida.

    Recently he received the Life Time Achievement Award from the BayBio Association of California.

    DR. MARIANO SANZ / CLINICAL ADVISOR

    Graduated in Medicine and Surgery from the Complutense University of Madrid. Specialty in Stomatology, Periodontics at the University of California, Los Angeles (UCLA) and DrMed (PhD) from the Complutense University of Madrid in 1985.

    Professor and Chair of Periodontology in the Complutense University of Madrid and Professor Type II in the University of Oslo (Norway).

    Visiting Professor at the Universities of Pennsylvania and University of California at Los Angeles (UCLA) in the United States and at Leuven and Kings College in Europe.

    Associate Editor of the Journal of Clinical Periodontology and author of more than 400 scientific publications and book chapters in Periodontics, Dental Implants and Dental Education.

    LINKEDIN PROFILE

    GET IN TOUCH WITH US

    IF YOU HAVE ANY QUESTIONS OR WOULD LIKE MORE INFORMATION, DON'T HESITATE TO REACH OUT.